Adam Michael Andruska, MD
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Andruska’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A135947 · Current
Licensed to practise in California · since 2015 · expires 2026-11-30 · Southern Illinois University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$36,236
Medicare paid this office $36,236 for 320 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 54 | $20,289 | $183 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $3,353 | $105 |
| Return visit (30+ min) | 16 | $1,845 | $88 |
| Short return visit (20+ min) | 15 | $888 | $59 |
| Test to examine how well the lungs exchange gases | 86 | $648 | $7 |
See all 12 services
| Critical care, first 30-74 minutes | 54 | $20,289 | $183 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $3,353 | $105 |
| Return visit (30+ min) | 16 | $1,845 | $88 |
| Short return visit (20+ min) | 15 | $888 | $59 |
| Test to examine how well the lungs exchange gases | 86 | $648 | $7 |
| Test to measure expiratory airflow and volume | 83 | $557 | $7 |
| Test to examine how well the lungs exchange gases | 75 | $542 | $7 |
| Test to determine lung volumes using sensors | 53 | $522 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 56 | $510 | $9 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 36 | $334 | $9 |
| Test to determine lung volumes using sensors | 28 | $306 | $11 |
| Test to measure expiratory airflow and volume | 28 | $179 | $6 |
Who their Medicare patients are
320 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 15% · Women 53% · Also on Medicaid 28% · Health risk score 2.13. At or below the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Coronary heart disease 45% · Heart failure 42% · COPD 41% · Atrial fibrillation 39% · Chronic kidney disease 37% · Diabetes 34% · Cancer 26% · Depression 23% · Dementia 13% · Stroke 10%.
The office billed $301,176, Medicare allowed $46,269 and paid $36,236; for 698 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 320 | 698 | 75 | 2.13 | $301,176 | $36,236 |
| 2023 | 294 | 635 | 73 | 1.96 | $239,906 | $29,492 |
| 2022 | 347 | 873 | 74 | 2.01 | $461,005 | $51,176 |
| 2021 | 339 | 847 | 73 | 1.93 | $354,686 | $41,469 |
| 2020 | 329 | 790 | 73 | 2.27 | $267,397 | $34,180 |
| 2019 | 161 | 349 | 73 | 1.90 | $56,702 | $9,077 |
| 2015 | 203 | 436 | 69 | 3.93 | $104,846 | $36,510 |
| 2014 | 175 | 366 | 67 | 2.87 | $87,850 | $31,056 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Critical care, first 30-74 minutes | 44 | $15,158 | $189 |
| Long return visit (40+ min) | 13 | $2,509 | $132 |
| Return visit (30+ min) | 18 | $1,987 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,511 | $108 |
| Test to examine how well the lungs exchange gases | 79 | $618 | $8 |
| Test to examine how well the lungs exchange gases | 74 | $574 | $8 |
| Test to determine lung volumes using sensors | 53 | $560 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 56 | $506 | $9 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 57 | $478 | $8 |
| Test to measure expiratory airflow and volume | 57 | $434 | $7 |
| Test to determine lung volumes using sensors | 35 | $329 | $9 |
| Test to measure expiratory airflow and volume | 28 | $204 | $7 |
2022: 14 services
| Critical care, first 30-74 minutes | 86 | $31,076 | $188 |
| Long return visit (40+ min) | 16 | $3,555 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $3,408 | $92 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 19 | $1,513 | $72 |
| Critical care, each additional 30 minutes | 12 | $1,439 | $96 |
| Return visit (30+ min) | 11 | $1,267 | $84 |
| Test to examine how well the lungs exchange gases | 132 | $1,050 | $8 |
| Test to determine lung volumes using sensors | 89 | $931 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 91 | $825 | $9 |
| Test to examine how well the lungs exchange gases | 61 | $505 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 43 | $415 | $9 |
| Test to measure expiratory airflow and volume | 46 | $343 | $7 |
| Test to measure expiratory airflow and volume | 41 | $309 | $8 |
| Test to determine lung volumes using sensors | 27 | $308 | $11 |
2021: 11 services
| Critical care, first 30-74 minutes | 63 | $25,774 | $195 |
| Long return visit (40+ min) | 12 | $2,685 | $141 |
| Test to determine lung volumes using sensors | 117 | $1,255 | $10 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 14 | $1,194 | $75 |
| Test to examine how well the lungs exchange gases | 142 | $1,172 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 120 | $1,130 | $9 |
| Test to examine how well the lungs exchange gases | 58 | $475 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 42 | $396 | $9 |
| Test to measure expiratory airflow and volume | 48 | $362 | $8 |
| Test to determine lung volumes using sensors | 28 | $309 | $11 |
| Test to measure expiratory airflow and volume | 32 | $256 | $7 |
2020: 10 services
| Critical care, first 30-74 minutes | 76 | $23,264 | $195 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 94 | $1,180 | $12 |
| Test to determine lung volumes using sensors | 94 | $1,123 | $11 |
| Test to examine how well the lungs exchange gases | 124 | $1,103 | $8 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $984 | $76 |
| Test to examine how well the lungs exchange gases | 79 | $616 | $8 |
| Test to measure expiratory airflow and volume | 66 | $453 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 41 | $448 | $11 |
| Test to determine lung volumes using sensors | 33 | $331 | $10 |
| Test to measure expiratory airflow and volume | 41 | $329 | $7 |
2019: 9 services
| Critical care, first 30-74 minutes | 19 | $4,834 | $193 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 62 | $725 | $12 |
| Test to determine lung volumes using sensors | 54 | $595 | $11 |
| Test to examine how well the lungs exchange gases | 67 | $553 | $8 |
| Test to examine how well the lungs exchange gases | 37 | $304 | $8 |
| Test to measure expiratory airflow and volume | 36 | $274 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 21 | $248 | $12 |
| Test to determine lung volumes using sensors | 16 | $178 | $11 |
| Test to measure expiratory airflow and volume | 15 | $120 | $8 |
2015: 6 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 74 | $11,756 | $159 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $9,211 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 68 | $8,766 | $56 |
| Hospital discharge day management, more than 30 minutes | 20 | $1,724 | $82 |
| Hospital discharge day management, 30 minutes or less | 19 | $1,025 | $54 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $580 | $31 |
2014: 6 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $8,887 | $159 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $8,421 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 65 | $7,307 | $56 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,724 | $108 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,083 | $83 |
| Hospital discharge day management, 30 minutes or less | 13 | $732 | $56 |
Medicaid work
$535 in 2024
Medicaid paid $535 for 76 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Diffusing capacity | 49 | $258 |
| EVALUATION OF WHEEZING | 14 | $183 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 13 | $94 |
| 2024 | 76 | 3 | 20 | $535 |
| 2023 | 41 | 2 | 14 | $320 |
| 2022 | 26 | 2 | 13 | $163 |
| 2021 | 50 | 2 | 20 | $249 |
| 2020 | 25 | 1 | 13 | $138 |
See the largest Medicaid services in earlier years
2023
| EVALUATION OF WHEEZING | 13 | $179 |
| Diffusing capacity | 28 | $141 |
2022
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 13 | $82 |
| Diffusing capacity | 13 | $81 |
2021
| Diffusing capacity | 36 | $166 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 14 | $83 |
2020
| Diffusing capacity | 25 | $138 |
Drugs they prescribed that Part D paid
$502,897
Pharmacies billed $502,897 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 150) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
76 generic and 74 brand-name prescriptions · $502,897 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Uptravi | 12 | $275,564 | $22,964 |
| Opsumit | 12 | $142,115 | $11,843 |
| Ambrisentan | 13 | $25,145 | $1,934 |
| Eliquis | 31 | $22,144 | $714 |
| Bosentan | 15 | $17,715 | $1,181 |
See all 8 drugs
| Uptravi | 12 | $275,564 | $22,964 |
| Opsumit | 12 | $142,115 | $11,843 |
| Ambrisentan | 13 | $25,145 | $1,934 |
| Eliquis | 31 | $22,144 | $714 |
| Bosentan | 15 | $17,715 | $1,181 |
| Sildenafil Citrate | 17 | $13,612 | $801 |
| Tadalafil | 12 | $365 | $30 |
| Furosemide | 12 | $55 | $5 |
Year by year
| 2024 | 150 | 18 | 0% (0) | 49% | $502,897 |
| 2023 | 150 | 21 | 0% (0) | 39% | $635,691 |
| 2022 | 151 | 16 | 0% (0) | 42% | $557,429 |
| 2021 | 70 | None | 0% (0) | 41% | $109,105 |
| 2020 | 26 | None | 0% (0) | None | $2,248 |
| 2015 | 166 | 43 | None | None | $11,774 |
| 2014 | 891 | 93 | 7% (58) | 22% | $48,575 |
| 2013 | 1,198 | 118 | 5% (61) | 20% | $61,606 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Uptravi | 12 | $290,698 | $24,225 |
| Bosentan | 12 | $92,843 | $7,737 |
| Ambrisentan | 12 | $72,956 | $6,080 |
| Tadalafil | 13 | $39,435 | $3,033 |
| Eliquis | 11 | $6,786 | $617 |
| Digoxin | 12 | $261 | $22 |
| Furosemide | 20 | $165 | $8 |
2022: 8 drugs
| Uptravi | 13 | $271,356 | $20,874 |
| Ambrisentan | 13 | $99,625 | $7,663 |
| Bosentan | 12 | $92,920 | $7,743 |
| Tadalafil | 12 | $41,311 | $3,443 |
| Xifaxan | 11 | $33,595 | $3,054 |
| Eliquis | 24 | $13,727 | $572 |
| Digoxin | 12 | $263 | $22 |
| Furosemide | 24 | $172 | $7 |
2021: 2 drugs
| Eliquis | 11 | $5,770 | $525 |
| Sildenafil Citrate | 20 | $2,234 | $112 |
2015: 1 drug
| Furosemide | 11 | $37 | $3 |
2014: 20 drugs
| Advair Diskus | 20 | $7,195 | $360 |
| Spiriva | 16 | $4,626 | $289 |
| Proair Hfa | 42 | $2,726 | $65 |
| Atorvastatin | 47 | $846 | $18 |
| Omeprazole | 34 | $451 | $13 |
| Bd Ultra-Fine Pen Needle | 12 | $442 | $37 |
| Carvedilol | 41 | $342 | $8 |
| Gabapentin | 24 | $328 | $14 |
| Pravastatin | 14 | $315 | $22 |
| Lisinopril | 44 | $307 | $7 |
| Metformin Hcl Er | 15 | $286 | $19 |
| Metformin | 25 | $233 | $9 |
| Metoprolol | 38 | $197 | $5 |
| Montelukast | 14 | $174 | $12 |
| Simvastatin | 24 | $172 | $7 |
| Ranitidine | 24 | $171 | $7 |
| Tramadol | 22 | $169 | $8 |
| Amlodipine Besylate | 35 | $163 | $5 |
| Losartan | 18 | $113 | $6 |
| Furosemide | 15 | $58 | $4 |
2013: 28 drugs
| Advair Diskus | 25 | $8,517 | $341 |
| Proair Hfa | 34 | $1,723 | $51 |
| Atorvastatin | 58 | $1,460 | $25 |
| Bd Ultra-Fine Pen Needle | 29 | $1,262 | $44 |
| Gabapentin | 17 | $821 | $48 |
| Omeprazole | 55 | $808 | $15 |
| Clopidogrel | 16 | $640 | $40 |
| Lisinopril | 87 | $625 | $7 |
| Montelukast | 23 | $518 | $23 |
| Simvastatin | 50 | $413 | $8 |
| Hydralazine | 15 | $406 | $27 |
| Losartan | 26 | $403 | $15 |
| Metformin | 43 | $393 | $9 |
| Carvedilol | 36 | $348 | $10 |
| Amlodipine Besylate | 51 | $319 | $6 |
| Metoprolol | 54 | $305 | $6 |
| Levothyroxine | 28 | $227 | $8 |
| Pravastatin | 17 | $214 | $13 |
| Finasteride | 11 | $210 | $19 |
| Ranitidine | 29 | $185 | $6 |
| Tramadol | 21 | $169 | $8 |
| Nitrostat | 13 | $150 | $12 |
| Venlafaxine Hcl Er | 11 | $147 | $13 |
| Lovastatin | 14 | $141 | $10 |
| Citalopram Hbr | 19 | $128 | $7 |
| Glipizide | 12 | $99 | $8 |
| Furosemide | 13 | $76 | $6 |
| Hydrochlorothiazide | 17 | $60 | $4 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1245526169
- Licence
- CA A135947, MO 2014017389California A135947: Current · expires 2026-11-30
- Trained
- Southern Illinois University School of Medicine, 2011
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X); Federal specialty code 207RC0200X (207RC0200X); Hospitalist (208M00000X)
- Mailing address
- 300 Pasteur Dr Rm H2143, Stanford, CA, 94305
- NPI first listed
- 2011-06-20
- NPI last updated
- 2019-08-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1 Barnes Jewish Hospital Plz, Saint Louis, MO, 63110